Intravitreal injections (Avastin, Lucentis)

completely changed following the introduction of avastin.
Avastin and lucentis are drugs used for treating exudative maculopathy with great success. These medications can stop the disease’s development and, in some cases, even improve vision, They are injected inside the eye so that they can stop neovessels growth: this is typical of exudative maculopathy.

Injection is performed as an outpatient treatment in a few minutes; anyway, this process is performed in the operatory room in order to guarantee sterility.
More than one injections is needed in a timespan of 1 to 3 months, until vision quality settles.

The current therapeutic orientation consists in perform a cycle of 3 injections (loading phase) and then intervene again only in case of loss of vision or new liquid presence when performing OCT and angiography exams.

Maculopathy therapy with Avastin and Lucentis should be followed with extreme caution by heart patients. There is also a risk linked to intravitreal injection that is infection (endophthalmitis, about 1.5%).

Christian Altadonna, Palermo

Votazione: Eccellente
I am almost 19 and last year Dr. Badalà diagnosed me with a macular degeneration due to strong myopia.

I received an Eylea Intravitreal injection and my view improved a lot and in a few months; I immediately got back... Keep on reading this review to my normal activities, for example using PC or watching television.

I suggest it because it has changed my life, it has improved it, and, in addition, Dr. Badalà has the ability to involve his patients in every way.